This expert perspective evaluates the clinical role of PSMA PET in prostate cancer management — including initial staging of higher-risk disease and biochemical recurrence — and examines barriers to equitable access across European health care systems.
PSMA PET outperforms conventional imaging in disease characterization and increasingly drives treatment planning and patient stratification, but access remains uneven due to variability in reimbursement, regulatory frameworks, tracer availability, imaging capacity, and local expertise.
Expert perspective only — no original clinical data, no patient-level outcomes, and findings are largely Europe-focused, limiting generalizability to other health systems.
Clinicians should advocate for timely PSMA PET referral in eligible patients with higher-risk disease or biochemical recurrence, recognizing that access gaps may directly compromise staging accuracy and treatment selection. Institutional and policy-level engagement is needed to close equity gaps in molecular imaging access.
